Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

ratory and clinical members of the CLL and lymphoma program at OSU are very excited to be involved with the pre-clinical and clinical development of PCI32765."

Recent and Upcoming Milestones and Program Updates

  • Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, results from first in human phase I trial were presented at an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting that took place in Chicago, Illinois in June 2010. These results were also presented at the European Hematology Association in Barcelona, Spain in June 2010. The presentations reported data from the ongoing open-label, dose-escalation study of PCI-32765 in recurrent B cell malignancies.
  • Trial Results as of August 31, 2010: In the first 6 dose cohorts, a total of 47 relapsed/refractory and progressing patients with a variety of B cell malignancies were enrolled. Forty-one of the enrolled patients had an on-treatment tumor assessment of therapy and are evaluable as of August 31, 2010. Twenty-one of these evaluable patients had a complete or partial response as their best response and eleven patients had stable diseases. This equates to a response rate of 51% in the evaluable patients (69% in CLL, 75% in Mantle, 42% in Follicular, 33% in Marginal and 38% in DLBCL). On an intent-to-treat ("ITT") basis the overall response rate ("ORR") was 45%.

  • NComplete ResponsePartial ResponseStable DiseaseProgressive DiseaseNot Evaluable*Evaluable RR %ORR %
    ITT**Chronic/Small  Lymphocytic Leukemia (CLL/SLL)15

    1

    8

    4

    0

    2

    69%
    (9/13)

    60%
    (9/15)Mantle Cell (MCL)4

    2

    1

    1

    075%
    (3/4)

    75%
    (3/4)Diffuse Large B Cell Lymphoma (DLBCL)83

    1

    438%
    (3/8)

    38%
    (3/8)Follicular Lymphoma (FL)15

    1

    4

    3

    4

    3

    42%
    (5/12)

    33%
    (5/15)Margi
    '/>"/>

    SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... Jan. 22, 2015  BiOptix is pleased to announce the ... President of Chemistry and Biochemistry. Scott joins the company after ... and Amgen throughout the course of his nearly 20 ... "Scott is a nationally recognized thought leader in the ...
    (Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
    (Date:1/22/2015)... OAKS, Calif. , Jan. 22, 2015  Amgen (NASDAQ: ... and full year 2014 financial results on Tuesday, Jan. 27, 2015, ... be followed by a conference call with the investment community at ... Robert A. Bradway , chairman and chief executive officer, and ...
    Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
    (Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
    (Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
    (Date:1/22/2015)... NY (PRWEB) January 22, 2015 As interest ... overall health care gains momentum worldwide, Rev. Eric J. ... HealthCare Chaplaincy Network (HCCN), will be the keynote speaker ... care in Israel’s public health system. , The conference, “Hope ...
    (Date:1/22/2015)... 2015 Compare-autoinsurance.org has released a new blog post ... auto insurance policy . , Some types of vehicles ... check the newly released blog post to see if their vehicle ... damaged vehicles are some of the cars that cannot be covered ...
    (Date:1/22/2015)... 2015 Step into a macabre world ... Museum of Virginia. Wicked Plants, the Museum’s latest featured ... 75 poisonous, carnivorous and diabolical plants inside of a ... uncover the biochemical, physical and neurological processes between botanicals ...
    Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
    ... NY) ─ A study of more than 3,000 children shows ... increased likelihood that children will develop allergies, according to a ... Journal of Allergy and Clinical Immunology . Researchers from ... headed the study. Researchers looked at the serum vitamin ...
    ... March 29 symposium at the New York Academy of Sciences, ... will feature a presentation by Daniel J. Thomasch, JD, national ... case decided by the Supreme Court yesterday in which the ... The case, Bruesewitz vs Wyeth, was brought by the ...
    ... WEDNESDAY, Feb. 23 (HealthDay News) -- Nearly three years after ... claimed two lives, U.S. epidemiologists have learned that speed is ... preventing further infection. But speed requires resources that ... the Feb. 23 online issue of the New England ...
    ... in The Endocrine Society,s Journal of Clinical Endocrinology & ... five times more likely to develop type 2 diabetes than ... regardless of the patient,s fasting insulin levels, which were used ... fatty liver has become more appreciated as a sign of ...
    ... enhance athletic performance have found that bovine colostrum can ... gut syndrome., Their findings, published in the March ... Liver Physiology , could have positive implications not just ... A research group led by Ray Playford, Professor of ...
    ... Serena Gordon HealthDay Reporter , WEDNESDAY, Feb. 23 ... findings of other scientists, researchers have found that children who ... asthma. The risk of asthma was reduced by as ... researchers suspect that it,s the diversity of exposure to different ...
    Cached Medicine News:Health News:Low vitamin D levels linked to allergies in kids 2Health News:Experts explore vaccines: Science, legal, social issues at New York Academy of Sciences 2Health News:Fast Response Crucial in Outbreaks of Food-Borne Illness: Study 2Health News:Fast Response Crucial in Outbreaks of Food-Borne Illness: Study 3Health News:Fatty liver may herald impending Type 2 diabetes 2Health News:Is dairy colostrum the key to Olympic success? 2Health News:Kids Growing Up on Farms Less Likely to Have Asthma 2Health News:Kids Growing Up on Farms Less Likely to Have Asthma 3
    ... basic laboratory system for pH and temperature ... obtained when used with a temperature probe ... and easy one and two-point calibration with ... (pH 1.68, 4.00, 7.00, 10.01 and 12.45) ...
    ... The F340 is a basic laboratory ... compensated pH results can be obtained when ... a 3-in-1 electrode. • Fast and easy ... buffer recognition for five buffers (pH 1.68, ...
    ... is a dual-monochromator, multi-detection microplate reader ... 6-384 microplate reading capability. Detection modalities ... intensity (FI) and have optical performance ... or spectrophotometer. Endpoint, kinetic, spectrum and ...
    ... Detection of PCR, cDNA and Oligonucleotides The ... reader for a variety applications that are quantified ... suitable to handle assays in Microplate formats ... tubes Cuvettes Independent whether you ...
    Medicine Products: